tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

Health care · Software · NYSE

VEEVVeeva Systems

Compare with peers → Embed
The 10-K against last year's

137 changes: 22 added, 17 removed, 97 reworded, 1 quiet changes

10-K Mar 20, 2026 vs Mar 24, 2025
Risk FactorsRedline ↓
21.5%
of the text changed · 17,426 words now
13.0%
of the text changed · 5,878 words now
Legal ProceedingsRedline ↓
71.4%
of the text changed · 243 words now
Accounting PoliciesRedline ↓
13.5%
of the text changed · 3,098 words now

10-K 0001393052-26-000014 (2026-03-20) vs 10-K 0001393052-25-000022 (2025-03-24)

The redline

The paragraph that changed most in each section

Marked against last year's 10-K: cut words struck through, new words highlighted and underlined.

Risk Factors 375 words changed in this paragraph; it is 41% similar to last year's version.
Our subscription orders are generally billed at the beginning of the subscription period in annual or quarterly increments, which means the annualized value of such orders may not be completely reflected in deferred revenue at any single point in time. Many of our customers, including many of our large customers, are billed on a quarterly basis and therefore a substantial portion of the value of contracts billed on a quarterly basis will not be reflected in our deferred revenue at the end of any given quarter. Also, particularly with respect to expansion orders for our Commercial Solutions, because the term of orders for additional end users or applications is commonly less than one year to align to the renewal date of existing Commercial Solutions orders, the annualized value of such orders may not be completely reflected in deferred revenue at any single point in time. We have also agreed from time to time, and may agree in the future, to allow customers to change the renewal dates of their orders to, for example, align more closely with a customer’s annual budget process or to align with the renewal dates of other orders placed by other entities within the same corporate control group, or to change payment terms from annual to quarterly, or vice versa. Such changes may result in an order of less than one year as necessary to align all orders to the desired renewal date and, thus, may result in a lesser increase to deferred revenue compared to if the adjustment had not occurred. Additionally, changes in renewal dates may change the fiscal quarter in which deferred revenue associated with a particular order is booked. Accordingly, we do not believe that changes on a quarterly or annual basis in deferred revenue, calculated billings, or normalized billings are precise indicators of the underlying momentum of our business or future revenues. We believe that our subscription revenue guidance and normalized billings guidance for the full fiscal year are the best indicators of the momentum of our business or future revenues. Please note that we define the term calculated billings for any period to mean revenue for the period plus the change in deferred revenue from the immediately preceding period minus the change in unbilled accounts receivable from the immediately preceding period. We define the term normalized billings for any period to mean calculated billings adjusted for the impact of (i) term changes in our customer renewals, such as changes to renewal date (for example, changing the renewal date of multiple products to be coterminous) or changes to billing frequency (for example, changing from annual to quarterly billings), and (ii) delayed renewals that have closed and billed after the period end. However, many companies that provide cloud-based software report changes in deferred revenue or billings as key operating or financial metrics, and it is possible that analysts or investors may view these metrics as important. Thus, any changes in our deferred revenue balances or deferred revenue trends could adversely affect the market price of our common stock.

Source: Item 1A, 10-K 0001393052-26-000014 vs Item 1A, 10-K 0001393052-25-000022

Accounting Policies 137 words changed in this paragraph; it is 39% similar to last year's version.
In November 2024, September 2025, the FASB issued ASU 2024-03, Income Statement 2025-06, Intangibles - Reporting Comprehensive Income Goodwill and Other - Expense Disaggregation Disclosure Internal-Use Software (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure, in the notes 350-40): Targeted Improvements to the financial statements, of additional information about certain Accounting for Internal-Use Software, which modernizes the recognition and capitalization framework for internal-use software development costs and expenses in order to reflect current software development practices. The amendments also require Subtopic 360-10 disclosures for interim and annual reporting periods. all capitalized internal-use software costs. This new standard is effective for our fiscal year beginning on February 1, 2027 2028 and interim periods beginning on February 1, 2028 within that fiscal year and may be applied prospectively, retrospectively, or using a modified transition approach. The Company will early adopt ASU 2025-06 in the fiscal quarter ended April 30, 2026 on a prospective basis and retrospective application is permitted. basis. We are currently evaluating this do not expect the adoption of ASU 2025-06 to determine its have a material impact on our disclosures. consolidated financial statements.

Source: Item 8, Note 1 – Summary of Business and Significant Accounting Policies, 10-K 0001393052-26-000014 vs Item 8, Note 1 – Summary of Business and Significant Accounting Policies, 10-K 0001393052-25-000022

MD&A 113 words changed in this paragraph; it is 66% similar to last year's version.
The increase in subscription services revenues consisted of $274 $247 million of subscription services revenue attributable to R&D and Quality Solutions and $109 $153 million of subscription services revenue attributable to Commercial Solutions. The increase in subscription services revenue attributable to R&D solutions and Quality Solutions was primarily due to driven by the expanding use by existing customers of our Veeva Development Cloud products by both existing and new customers. The increase in subscription services revenue attributable to Commercial Solutions was primarily due to expanding use of our Veeva Commercial Quality Cloud products by both existing and new customers and, to a lesser extent, due to higher prices in connection with our annual inflation adjustment. adjustment for Veeva Development Cloud products. The increase in subscription revenue attributable to Commercial Solutions was primarily driven by the expanding use by existing customers of our Veeva Commercial Cloud and Veeva Data Cloud products and, to a lesser extent, due to higher prices in connection with our annual inflation adjustment for Veeva Commercial Cloud products. The geographic mix of subscription services revenues was 60% from North America, 28% from Europe, and 12% from other locations, primarily Asia Pacific, for the fiscal year ended January 31, 2026, as compared to 59% from North America, 28% from Europe, and 13% from other locations, primarily Asia Pacific, for the fiscal year ended January 31, 2025, as compared to 58% from North America, 27% from Europe, and 15% from other locations, primarily Asia Pacific, for the fiscal year ended January 31, 2024. 2025.

Source: Item 7, 10-K 0001393052-26-000014 vs Item 7, 10-K 0001393052-25-000022

Legal Proceedings New paragraph this year (88 words), with no similar paragraph last year.
On August 13, 2025, Veeva and IQVIA entered into a settlement agreement that resolved all ongoing litigations between Veeva and IQVIA. Prior to that, IQVIA and Veeva had been involved in a series of litigations since 2017, including IQVIA Inc. v. Veeva Systems Inc. (No. 2:17-cv-00177) and IQVIA Inc. v. Veeva Systems Inc. (No. 2:19-cv-15517). Under the terms of the settlement agreement, neither party paid damages to the other party and both parties agreed to dismiss with prejudice all claims and counterclaims currently pending. Accordingly, all claims and

Source: Item 3, via Note 13 – Commitments and Contingencies, 10-K 0001393052-26-000014 vs Item 3, via Note 14 – Commitments and Contingencies, 10-K 0001393052-25-000022

Every change, by type

Sentences and paragraphs added, removed or reworded

Sentences and paragraphs of VEEV's Risk Factors and MD&A, 10-K 2026-03-20 against 10-K 2025-03-24. Each links to the text at sec.gov.

AddedRisk Factors
other markets. Our efforts may not be successful in creating further demand for our solutions outside of the United States or in effectively selling our solutions in the international markets we enter.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
We process personal data on behalf of our customers, who use our solutions to manage personal data of their employees, healthcare professionals, patients, and related individuals. We also process personal data as part of the Veeva Data Cloud offerings, which provide our customers with professionally relevant data related to healthcare providers and other industry professionals and stakeholders. In addition, we process personal data to provide services that allow healthcare marketers to reach their target audiences and to measure the impact of their media campaigns. In some cases, the personal data that we process includes sensitive personal data, such as health data.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
Many countries and governmental bodies have adopted or may adopt laws and regulations governing our processing of personal and other data, making compliance an increasingly complex task. For example, we are regulated under the European General Data Protection Regulation (“EU GDPR”) and the United Kingdom’s General Data Protection Regulation (“UK GDPR”), as amended by the Data (Use and Access) Act of 2025, where we act as a data controller for our data products and a data processor with respect to our software products. In China, we are regulated under China’s Personal Information Protection Law (“PIPL”), where we process data as an entrusted party on behalf of our customers who operate as data handlers. In certain cases, we are regulated under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) that covers protected health information collected or maintained by covered entities and their business associates. Additionally, many states in the U.S. have passed comprehensive privacy legislation, such as the California Consumer Privacy Act (amended by the California Privacy Rights Act). Some states in the U.S. also have passed legislation governing the processing of particular types of data, such as biometric data and certain other health-related data.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
These laws and regulations impose data subject notice or transparency requirements, mandated privacy and security standards, and registration obligations. They also grant rights to data subjects, such as allowing them to access, correct, delete, or opt out of the sale or sharing of their information. Some of these laws and regulations target certain types of marketing and advertising based on the use of personal information. For example, in response to the State of Washington’s My Health My Data Act, which placed significant restrictions on how businesses can collect, use, and disclose consumer health data, we added limitations to the audience segments on our Veeva Crossix data platform. Other states have considered, and in certain cases, enacted, similar laws.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
In 2025, the U.S. Department of Justice issued a final rule that places limitations, and in some cases prohibitions, on certain transfers of and access to certain personal data of U.S. persons by persons and entities located in China (and other designated countries) or controlled by a person or entity located in China (and other designated

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
countries). Additionally, the French governmental agency for health mandates a certification requiring that personal health data collected during healthcare activities be stored exclusively within the European Economic Area.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
These laws and regulations impose significant data protection obligations and carry substantial penalties for noncompliance. Furthermore, the application and interpretation of these laws and regulations are complex and, at times, unclear and inconsistent.

Read it in 10-K 2026-03-20 at sec.gov ↗

Show the other 7
AddedRisk Factors
As we expand our data product offerings into new jurisdictions, we are required to assess, monitor, and comply with additional laws and regulations related to our collection and processing of data, which may include new registration, consent, and notification obligations. In addition to our own processing of personal data, our customers expect that our solutions can be used to enable their compliance with applicable data protection, data privacy, and cybersecurity laws and regulations.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
Salesforce also has the right, in certain circumstances, to terminate the wind-down period early, including in the event of a material breach of the agreement by us, or if Salesforce is subjected to third-party intellectual property infringement claims based on our solutions (except to the extent based on the Salesforce platform) or our

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
trademarks and we do not remedy such infringement in accordance with the agreement. Also, if we are acquired by specified companies, Salesforce may terminate the agreement upon notice of not less than 12 months. If the Salesforce platform for Veeva CRM becomes unavailable earlier than we anticipate, our business and operations would be adversely affected.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedRisk Factors
•data acquisition costs associated with our Veeva Compass offering and costs incurred with our use of large language models associated with our Veeva AI offering;

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedMD&A
In January 2026, our board of directors authorized a share repurchase program of up to $2 billion of our outstanding shares of common stock. Under the program, we may repurchase shares of common stock from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, in accordance with applicable securities laws and other restrictions, including Rule 10b-18 under the Exchange Act. The timing and total amount of any share repurchases depend upon business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. The share repurchase program has a term of two years, may be suspended or discontinued at any time, and does not obligate us to acquire any amount of common stock. Any repurchased shares of common stock will be retired. The repurchase program will be funded using our working capital.

Read it in 10-K 2026-03-20 at sec.gov ↗

AddedMD&A
During the fiscal year ended January 31, 2026, we repurchased and subsequently retired 801,735 shares of our common stock for an aggregate amount of approximately $180 million.

Read it in 10-K 2026-03-20 at sec.gov ↗

Next Related parties →